3900 Gantz Rd
9 articles with Forge Biologics
Forge Biologics announced today that it will be delivering a company presentation at BIO Digital, hosted by the Biotechnology Innovation Organization, being held June 10-11 and 14-18, 2021.
Forge Biologics Expands Gene Therapy Leadership Team with Appointment of John Maslowski as Chief Commercial Officer
Forge Biologics, a gene therapy-focused contract development and manufacturing organization (CDMO), announced today the appointment of John Maslowski to the newly created role of Chief Commercial Officer.
Forge Biologics, a gene therapy-focused contract development and manufacturing organization, announced today that its CEO, President and Co-Founder Timothy J. Miller, Ph.D., will present at the Jefferies Virtual Healthcare Conference, being held June 1-4, 2021. Dr. Miller will provide a company overview, detailing the company’s growth from its launch in July, 2020 with $40 million in Series A financing
Forge Biologics to Present at the American Society of Gene and Cell Therapy’s 24 th Annual Meeting
Financing led by RA Capital Management with participation from Perceptive Advisors, Surveyor Capital (a Citadel company), Octagon Capital, Marshall Wace, and Drive Capital Proceeds to accelerate the expansion of the contract development and manufacturing organization (CDMO) capacity for production of cGMP adeno-associated viruses (AAV)
Forge Biologics to Present at Chardan’s 5 th Annual Genetic Medicines Manufacturing Summit
- Forge Biologics, a cGMP manufacturing and development company, announced today that Timothy J. Miller , Ph.D., Chief Executive Officer, President, and Co-Founder will present at the annual Cell & Gene Meeting on the Mediterranean, which will be held virtually April 6-9, 2021 .
Forge Biologics Receives FDA Fast Track, Orphan Drug, and Rare Pediatric Disease Designations for FBX-101 Gene Therapy for Patients with Krabbe Disease
- The FDA has granted Fast Track Designation, Rare Pediatric Disease Designation, and Orphan Drug Designation to FBX-101 for treatment of patients with Krabbe disease - FBX-101 is a first-in-human gene therapy utilizing an adeno-associated virus (AAV) to deliver a functioning copy of the GALC gene intraveniously to cells in the central nervous system (CNS) and peripheral organs
BioSpace is proud to present its NextGen Bio “Class of 2021,” a list of up-and-coming life sciences companies in North America that recently launched.